Adderall is a combined drug containing salts of the two enantiomers of amphetamine, a central nervous system (CNS) stimulant of the phenethylamine class. Adderall is used in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and narcolepsy. It is also used as an athletic performance enhancer and cognitive enhancer, and recreationally as an aphrodisiac and …
NNI-351 is an active oral inhibitor of DYRK1A and a neurogenesis enhancer that is being developed by NeuroNascent, Inc. for the treatment of Down syndrome, depression and post-traumatic stress disorder (PTSD). [1] [2] Beginning in 2017, it is in the preclinical development phase and has not yet progressed in human clinical trials
The cell transcription factor CREB (cAMP response element binding protein) [1] helps in the learning and stabilization and recovery of long-term memories based on fear. This is mainly due to its expression in the hippocampus and amygdala. Studies that support the role of CREB in cognition include those that eliminate the gene, reduce expression, or …
The nootropics (from nous mind and tropos bend) or nootropics are drugs , the drugs , plants and various substances having an action of modulation of physiology and psychology involving cognitive increase and that no or relatively little effect Health hazards at standard doses. Nootropics are promoted in transhumanism as a general means of improving living conditions, or for specific purposes, such as increased motivation. Since the year 2000, more substances (eg, rivastigmine , the galantamine or aniracetam) are …
The environmental enrichment studies how the brain is affected by stimulation of its centers of perception caused by everything that surrounds (including opportunities for social interaction). The brain , in a richer and more stimulating environment, has a greater number of synapses , and the dendrites in which they reside are more complex. This effect …
Basmisanil (INN) (developmental code names RG-1662, RO5186582) is a highly selective inverse agonist / negative allosteric modulator of GABA A receptors containing an α 5 subunit developed by Roche for the treatment of cognitive impairments associated with the syndrome Of Down. In August 2015, these are Phase II clinical trials for this indication.